NCT03531918View on ClinicalTrials.gov

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

July 1, 2021

Study Completion Date

November 1, 2021

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Cladribine

Given IV

DRUG

Cytarabine

Given IV

DRUG

Gemtuzumab Ozogamicin

Given IV

BIOLOGICAL

Recombinant Granulocyte Colony-Stimulating Factor

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Mitoxantrone Hydrochloride

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER

NCT03531918 - Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm | Biotech Hunter | Biotech Hunter